Clinical trial
A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection Due to Carbapenem Resistant Enterobacterales
NCT05905055 is registered in ClinicalTrials.gov with Meiji Seika Pharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection Due to Carbapenem Resistant Enterobacterales
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 22, 2023
- Completion date
- September 1, 2025
- Enrollment
- 126 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.
acute pyelonephritis, complicated intra-abdominal infection, complicated urinary tract infection, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia